FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Biblioteca de Peptidos

SS-31

Elamipretide / MTP-131 / Bendavia

Longevity & Anti-Aging

SS-31 (Elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing cristae structure and optimizing electron transport chain efficiency. Developed by Stealth BioTherapeutics, it represents a novel class of mitochondrial protective agents that do not rely on membrane potential for targeting. Its primary research applications include Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related mitochondrial dysfunction.

Mecanismo de Acción

Mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Binds cardiolipin to optimize electron transport chain function, reduce reactive oxygen species production, and restore mitochondrial bioenergetics.

Protocolos de Investigación

Para propósitos de investigación solo. No es asesoramiento médico.

Clinical trial protocols used 0.25mg/kg/hour IV infusion or 40mg daily subcutaneous injection. Research protocols use 1-5mg daily subcutaneously. Treatment duration varies by indication (4 weeks to 48 weeks in trials).

Notas de Investigación

Clinical Research Status

SS-31 (Elamipretide) has advanced through multiple Phase II and Phase III clinical trials, most notably the TAZPOWER trial for Barth syndrome and the MMPOWER trials for primary mitochondrial myopathy. The FDA granted Fast Track designation for Barth syndrome, though the compound has faced regulatory setbacks with initial NDA submissions requiring additional data. Stealth BioTherapeutics continues clinical development programs targeting heart failure with reduced ejection fraction and dry age-related macular degeneration.

Key Published Findings

In the TAZPOWER Phase II trial, elamipretide demonstrated improvements in 6-minute walk test distance and patient-reported outcomes in Barth syndrome patients over 12 weeks of subcutaneous administration. Preclinical studies have shown SS-31 reduces mitochondrial ROS production by 50-75%, improves ATP synthesis, and prevents cardiolipin peroxidation in ischemia-reperfusion models. Research in aged mice demonstrated that SS-31 treatment reversed age-related declines in skeletal muscle mitochondrial energetics and improved exercise tolerance within one hour of administration.

Safety Profile

SS-31 has demonstrated good tolerability in clinical trials at subcutaneous doses of 4mg and 40mg daily, with injection site reactions being the most common adverse event. Serious adverse events in trials have been infrequent and generally not attributed to the drug. The peptide has a favorable pharmacokinetic profile with rapid absorption, short half-life requiring daily dosing, and no evidence of accumulation or organ toxicity in long-term administration studies.

Drug Interactions & Contraindications

No significant drug-drug interactions have been identified in clinical studies to date, likely due to SS-31's mechanism of action at the mitochondrial membrane rather than via enzymatic pathways. The compound does not appear to interact with cytochrome P450 enzymes or common drug transporters. Caution may be warranted in patients taking other mitochondrial-targeted compounds, though formal interaction studies are limited.

Comparison to Related Compounds

Unlike CoQ10 and MitoQ which require mitochondrial membrane potential for uptake, SS-31 concentrates in mitochondria independent of membrane potential, making it effective even in damaged or dysfunctional mitochondria. MitoQ is a ubiquinone-based antioxidant targeting the matrix, while SS-31 specifically targets the inner membrane cardiolipin interface. SS-31's mechanism of stabilizing cardiolipin microdomains is fundamentally different from traditional antioxidants, addressing structural rather than purely redox-related mitochondrial dysfunction.

Community Observations

Research peptide users report noticeable improvements in exercise capacity and subjective energy levels within the first week of subcutaneous SS-31 administration at 2-5mg daily. The compound has gained significant interest in the longevity community due to preclinical data showing rapid reversal of age-related mitochondrial decline. Users note that SS-31 is relatively expensive and difficult to source compared to other peptides, limiting widespread adoption outside clinical trial settings.

Media Vida

~4-6 hours

Reconstitución

Bacteriostatic water (BAC)

Almacenamiento

Liofilizado

Refrigerate 2-8C. Protect from light.

Reconstituído

Refrigerate 2-8C. Use within 14 days.

Estado Legal EE.UU.

Research chemical (in clinical trials)

También Se Conoce Como

ElamipretideMTP-131Bendavia

Preguntas frecuentes

¿Qué es SS-31?

SS-31 (Elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing cristae structure and optimizing electron transport chain efficiency. Developed by Stealth BioTherapeutics, it represents a novel class of mitochondrial protective agents that do not rely on membrane potential for targeting. Its primary research applications include Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related mitochondrial dysfunction.

¿Cómo funciona SS-31?

Mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Binds cardiolipin to optimize electron transport chain function, reduce reactive oxygen species production, and restore mitochondrial bioenergetics.

¿Cuál es el estado regulatorio de SS-31 en EE. UU.?

Research chemical (in clinical trials)

¿Cuál es la vida media de SS-31?

~4-6 hours

¿Qué otros nombres tiene SS-31?

Elamipretide, MTP-131, Bendavia

Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.

Leer aviso completo